Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;8(6):e389-e392.
doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Affiliations

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Sarah Bird et al. Lancet Haematol. 2021 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

MK reports grants and personal fees from Bristol Myers Squibb/Celgene, personal fees and travel support from Amgen, Janssen, and Takeda, and personal fees from AbbVie, GSK, Karyopharm, and Seattle Genetics, outside the submitted work. CPaw reports personal fees and non-financial support from Amgen, Celgene, Janssen, and Sanofi, and non-financial support from Oncopeptides, outside the submitted work. KB reports personal fees from Celgene, GlaxoSmithKline, Janssen, and Takeda, outside the submitted work. All other authors declare no conflicts of interest. We thank David Cairns for providing statistical advice. We acknowledge National Health Service funding to the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research (ICR). SB is a Wellcome Trust Clinical Research Fellow, AS is an NIHR and ICR Clinical Lecturer, and CPaw is a Cancer Research UK Clinician Scientist.

References

    1. Cook G, John Ashcroft A, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190:e83–e86. - PMC - PubMed
    1. Hultcrantz M, Richter J, Rosenbaum C, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. Blood Cancer Discov. 2020;1:234–243. - PMC - PubMed
    1. Monin-Aldama L, Laing AG, Muñoz-Ruiz M, et al. Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. medRxiv. 2021 doi: 10.1101/2021.03.17.21253131. published online March 17. (preprint). - DOI
    1. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021;396:1979–1993. - PMC - PubMed
    1. Walsh EE, Frenck RW, Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383:2439–2450. - PMC - PubMed

LinkOut - more resources